Search Clinical Trials in the European Union

Duration
16-20 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
41-60 of 112 trials

Sickle Cell Disease: Etavopivat Treatment Study

We are evaluating how well etavopivat works for adolescents and adults with sickle cell disease. The study aims to see if it improves symptoms and quality of life compared to a placebo.

Sickle Cell Disease>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Narsoplimab for Children with High-Risk Stem Cell Transplant Complications

We are studying whether narsoplimab can improve survival and safety in children with thrombotic microangiopathy after stem cell transplants. This trial will help us understand how well this treatment works and its effects on young patients.

Thrombotic Microangiopathy1-2 yearsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyPediatrics

Early Alzheimer's Disease: Sabirnetug Infusions

We are studying whether intravenous sabirnetug can slow cognitive decline in people with early Alzheimer's disease compared to a placebo. This trial aims to find new ways to help manage symptoms and improve quality of life.

Early Alzheimer's Disease1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Chronic Lymphocytic Leukemia: Acalabrutinib Treatment Study

We are investigating whether acalabrutinib is safe and effective for adults with chronic lymphocytic leukemia and heart problems. This study compares it to other treatment options available for these patients.

Chronic Lymphocytic Leukaemia with Cardiac Impairment>2 yearsMonitoring phase (IV)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteCardiologyHematology

Long-Term Study of Galapagos CAR T-Cell Therapies

We are evaluating the long-term safety and effectiveness of Galapagos CAR T-cell therapies in patients. This study aims to understand how these treatments work over many years.

Relapsed/Refractory B-Cell Non-Hodgkin LymphomaRelapsed/Refractory Multiple MyelomaRelapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Myotonic Dystrophy Type 1: DYNE-101 Treatment Study

We are evaluating the safety and effects of a new treatment, DYNE-101, for people with Myotonic Dystrophy Type 1. The study aims to see how it impacts muscle health and overall well-being.

Myotonic Dystrophy>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurologyOrthopedics and Traumatology

Crigler-Najjar Syndrome: GNT0003 Treatment Study

We are evaluating a new treatment called GNT0003 for adults with severe Crigler-Najjar syndrome who need daily phototherapy. The study aims to see if this treatment is safe and effective for those with pre-existing antibodies.

Crigler-Najjar Syndrome>2 yearsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHepatologyInternal Medicine

Post-Stroke Spasticity: Dry Needling vs. Botulinum Toxin

We are exploring how Dry Needling and Botulinum Toxin type A affect spasticity in the lower limbs of stroke survivors. The study will also look at safety, muscle function, and quality of life.

Spasticity after Stroke3-6 monthsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesNeurologyOrthopedics and Traumatology

Lymphoma Treatment: MK-3475A Study

We are testing a new formulation of pembrolizumab for patients with relapsed or refractory classical Hodgkin lymphoma or primary mediastinal large B-cell lymphoma. The study aims to evaluate its effectiveness and safety compared to existing treatments.

Relapsed or Refractory Classical Hodgkin LymphomaRelapsed or Refractory Primary Mediastinal Large B-cell Lymphoma>2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Chronic Myelomonocytic Leukemia: New Treatment Combination Study

We are testing a combination of azacitidine, venetoclax, and tagraxofusp for patients with higher-risk chronic myelomonocytic leukemia. The study aims to evaluate how well this treatment works and its safety.

Chronic Myelomonocytic Leukemia1-2 yearsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesHematologyOncology

Hearing Loss in Children: DB-OTO Gene Therapy

We are testing a new gene therapy for children and infants with hearing loss due to specific genetic mutations. The study aims to see if it is safe and effective in improving their hearing and speech skills.

Congenital Hearing Loss1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesOtolaryngologyPediatrics

Hidradenitis Suppurativa: Sonelokimab Treatment Study

We are testing a new injectable medication, sonelokimab, for adults with moderate to severe hidradenitis suppurativa. The study aims to see if it can improve symptoms compared to a placebo.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementAllergologyDermatology

Crohn's Disease in Children: Mirikizumab Study

We are studying whether Mirikizumab can help children with moderately to severely active Crohn's Disease achieve better health compared to a placebo. This research aims to improve treatment options for young patients.

Crohn's Disease1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

Advanced Cancer: IO102-IO103 with Pembrolizumab

We are studying a new treatment combination for patients with metastatic non-small cell lung cancer, squamous cell carcinoma of the head and neck, or metastatic urothelial bladder cancer. The goal is to evaluate its effectiveness and safety as a first-line therapy.

Metastatic Squamous Cell Carcinoma of Head and NeckMetastatic Urothelial Bladder CancerMetastatic Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesOncology

Prurigo Nodularis: Povorcitinib Treatment Study

We are studying the effects of povorcitinib on itching and skin lesions in people with prurigo nodularis. The goal is to see if it improves symptoms and quality of life while ensuring safety.

Prurigo Nodularis1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Mantle Cell Lymphoma: Pirtobrutinib and Rituximab Study

We are evaluating a new treatment combining pirtobrutinib and rituximab for patients with indolent Mantle Cell Lymphoma. The study aims to determine its effectiveness and safety compared to standard therapies.

Mantle Cell Lymphoma1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Severe Asthma: Tezepelumab Medication Study

We are studying if tezepelumab can help patients aged 12 to 80 with severe asthma reduce their daily medication while keeping their symptoms under control.

Severe Asthma1-2 yearsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicinePulmonology

Triple Negative Breast Cancer: Sacituzumab Govitecan and Pembrolizumab Study

We are testing a new treatment combination for patients with triple negative breast cancer who have residual disease after surgery. The study aims to see if this combination improves survival compared to standard treatment options.

Triple Negative Breast Cancer3-6 monthsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Crohn's Disease: SAR441566 Treatment Study

We are investigating how different doses of SAR441566 affect symptoms and health in adults with moderate to severe Crohn's disease. This study aims to find out if the medication can help improve patients' quality of life and overall condition.

Crohn's Disease1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Metastatic Renal Cell Carcinoma: Temferon Gene Therapy

We are testing a new gene therapy using modified stem cells for patients with metastatic renal cell carcinoma. The study aims to evaluate the safety and biological response to a single dose of Temferon.

Metastatic Kidney Cancer1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHematologyOncology